Examining the effect of pipotiazine palmitate discontinuation on patients with psychosis after 12 months

When the monthly injectable drug for treatment of psychosis, pipotiazine palmitate, was discontinued on 2015 from UK markets due to a global shortage of the active pharmaceutical ingredient, users were obliged to swap to an alternative antipsychotic with the subsequent risk of relapse. The main aim of this project is to investigate the number of relapse measured by the number of admissions, number of days spent in hospital, number of referrals to home treatment teams and number of different antipsychotics received after pipotiazine palmitate was taken out of the market.